June 17th 2025
With more than 100 next-generation biologics set to lose patent exclusivity in the next 15 years, there is widespread agreement that developing biosimilars for these therapies will benefit society as a whole.
Sartorius Stedim's New Testing Services to Focus on mAbs and biosimilars
May 5th 2017Operated by BioOutsource, Sartorius’ subsidiary, the Glasgow, UK-based service center will offer physicochemical properties and structural attributes testing and allow clients to perform structural and functional analyses in parallel.
Sandoz’s Rituximab and Etanercept Biosimilars Recommended for European Approval
April 24th 2017Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions recommending the approval of its biosimilars rituximab and etanercept in Europe, for the same indications as the respective reference medicines.